###begin article-title 0
###xml 51 59 <span type="species:ncbi:9606">patients</span>
New horizons: NT-proBNP for risk stratification of patients with shock in the intensive care unit
###end article-title 0
###begin p 1
###xml 773 781 <span type="species:ncbi:9606">patients</span>
###xml 964 972 <span type="species:ncbi:9606">patients</span>
B-type natriuretic peptide (BNP) and amino-terminal pro-BNP (NT-proBNP) are promising cardiac biomarkers that have recently been shown to be of diagnostic value in decompensated heart failure, acute coronary syndromes and other conditions resulting in myocardial stretch and volume overload. In view of the high prevalence of cardiac disorders in the intensive care unit, the experience of elevated natriuretic peptide levels in the critically ill might be of enormous diagnostic and therapeutic value. BNP and NT-proBNP levels rise to different degrees in critical illness and may also serve as markers of severity and prognosis in diseases beyond acute or chronic heart failure. The diagnostic and prognostic use of natriuretic peptides in the intensive care setting for patients with various forms of shock could be an attractive alternative as noninvasive markers of cardiac dysfunction that could obviate the need for pulmonary artery catheterization in some patients.
###end p 1
###begin p 2
See related research article 
###end p 2
###begin title 3

###end title 3
###begin p 4
###xml 21 34 21 34 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Critical Care</italic>
###xml 59 60 59 60 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 161 169 <span type="species:ncbi:9606">patients</span>
###xml 332 340 <span type="species:ncbi:9606">patients</span>
###xml 493 501 <span type="species:ncbi:9606">patients</span>
###xml 690 698 <span type="species:ncbi:9606">patients</span>
In a recent issue of Critical Care, Januzzi and coworkers [1] report the results of a prospective cohort study, evaluating natriuretic peptides in various shock patients in the intensive care unit (ICU). The authors found no correlation between elevated levels of amino-terminal pro-BNP (NT-proBNP) and high filling pressures among patients with shock within the ICU, but higher values were reported to be strongly associated with death. A low level of NT-proBNP, however, identified low risk patients, who were less likely to benefit from pulmonary artery catheterization (PAC). The authors posed the question, therefore, whether NT-proBNP measurements can replace the need for PAC in ICU patients.
###end p 4
###begin p 5
###xml 145 146 145 146 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 392 393 392 393 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 549 550 549 550 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 662 663 662 663 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 1242 1243 1242 1243 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 1244 1245 1244 1245 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 106 114 <span type="species:ncbi:9606">patients</span>
###xml 619 627 <span type="species:ncbi:9606">patients</span>
###xml 798 806 <span type="species:ncbi:9606">patients</span>
###xml 877 885 <span type="species:ncbi:9606">patients</span>
###xml 995 1002 <span type="species:ncbi:9606">patient</span>
###xml 1143 1150 <span type="species:ncbi:9606">patient</span>
Brain natriuretic peptide (BNP) has been shown to be a useful cardiac biomarker for the identification of patients with suspected heart failure [2]. Elevated serum levels have been described in both left ventricular (LV) systolic and diastolic dysfunction as well as in right ventricular pressure overload states, such as pulmonary embolism, cor pulmonale and primary pulmonary hypertension [3]. BNP and its amino-terminal fragment NT-proBNP are markers of LV dysfunction, and elevated levels aid in discriminating cardiac from non-cardiac dyspnea [2]. Peptide levels also correlate with LV filling pressures (LVFP) in patients with depressed systolic function [4]. However, it is unclear whether BNP or NT-proBNP correlate with pulmonary capillary wedge pressure in a population of critically ill patients with a broad range of life-threatening diagnoses. Many critically ill patients have clinical and radiographic findings that cast doubt on LVFP. PAC has been used to measure LVFP and guide patient management. However, given its cost, complications, and evidence from recent studies that it has either a neutral or negative effect on ICU patient outcome, a reliable non-invasive method or parameter for the estimation of LVFP is needed [5,6].
###end p 5
###begin p 6
###xml 71 72 71 72 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 537 538 537 538 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 539 541 539 541 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 664 665 664 665 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 666 668 666 668 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 0 8 <span type="species:ncbi:9606">Patients</span>
###xml 100 108 <span type="species:ncbi:9606">patients</span>
###xml 279 287 <span type="species:ncbi:9606">patients</span>
###xml 468 476 <span type="species:ncbi:9606">patients</span>
###xml 644 651 <span type="species:ncbi:9606">patient</span>
Patients with various forms of shock have a high mortality in the ICU [7]. One method of evaluating patients with shock is invasive hemodynamic monitoring with PAC. In the modern era, however, non-invasive methods for estimating cardiac filling pressures and hemodynamics in ICU patients with shock, such as biomarkers capable of predicting prognosis, are coming to light. Several studies have shown that levels of the neurohormones BNP and NT-proBNP are increased in patients with cardiac dysfunction and severe sepsis or septic shock [8-12]. Moreover, these studies have shown that NT-proBNP can serve as an early marker of prognosis in this patient population [8,11].
###end p 6
###begin p 7
###xml 34 36 34 36 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 62 63 62 63 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 464 465 464 465 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 466 468 466 468 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 561 575 561 575 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Critical Care </italic>
###xml 576 577 576 577 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 770 771 770 771 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 772 774 772 774 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 415 423 <span type="species:ncbi:9606">patients</span>
###xml 651 659 <span type="species:ncbi:9606">patients</span>
###xml 899 907 <span type="species:ncbi:9606">patients</span>
Similar to previous examinations [13], Januzzi and coworkers [1] demonstrated that elevated levels of NT-proBNP were strongly associated with the risk of death in the ICU, and were even stronger predictors of death than APACHE II scores. It is doubtful, however, whether BNP or NT-proBNP correlate with invasively measured hemodynamic parameters, such as pulmonary capillary wedge pressure or low cardiac output in patients with various types of shock in the ICU [1,14]. In agreement with the findings reported by Jannuzzi and coworkers in the present issue of Critical Care [1], previous investigators reported that lower levels of NT-BNP identified patients with lower risk and better prognosis and that they may differentiate survivors from non-survivors in the ICU [8,11]. Thus, Januzzi and coworkers suggested that low NT-proBNP concentrations may be useful indicators to avoid PAC in low risk patients in the ICU.
###end p 7
###begin p 8
###xml 231 233 231 233 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 292 294 289 291 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 317 319 314 316 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 589 591 586 588 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 631 633 628 630 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 77 85 <span type="species:ncbi:9606">patients</span>
###xml 965 973 <span type="species:ncbi:9606">patients</span>
###xml 1106 1114 <span type="species:ncbi:9606">patients</span>
Several mechanisms account for increased natriuretic peptide levels in shock patients and for the observed lack of association between natriuretic peptides and cardiac filling pressures and hemodynamics. First, lipopolysaccharide [15] and proinflammatory cytokines such as interleukin-1beta [16] and cardiotrophin-1 [17] up-regulate transcription of the gene encoding BNP. Second, wall stretch can activate the Janus kinase/signal transducer and activator of transcription (JAK/STAT) pathway in cardiomyocytes; this activation augments IL-6 mRNA expression and consecutively IL-6 release [18]. According to Witthaut and collegues [10], who found a correlation between levels of natriuretic peptides and interleukin-6 plasma levels, the upregulation of IL-6 may effect cardiac release of natriuretic peptides. Thus, plasma levels of natriuretic peptides are not only affected by LV function, but also by secretion of inflammatory cytokines such as IL-6 in ICU shock patients. However, future studies evaluating the precise mechanisms responsible for enhanced natriuretic peptide secretion in critically ill patients are still needed.
###end p 8
###begin p 9
###xml 18 26 <span type="species:ncbi:9606">patients</span>
###xml 447 455 <span type="species:ncbi:9606">patients</span>
###xml 564 571 <span type="species:ncbi:9606">patient</span>
###xml 642 650 <span type="species:ncbi:9606">patients</span>
In critically ill patients, the use of PAC neither increases overall mortality or days in hospital nor confers benefit. Despite almost 20 years of randomized clinical trials, a clear benefit leading to improved survival from the use of PAC has not been proven. The neutrality of PAC for clinical outcomes may result from the absence of effective evidence-based treatment regimens according to PAC information across the spectrum of critically ill patients. Further clinical trials should lead to the establishment of treatment protocols for the use of PAC in this patient population. The additional measurement of NT-proBNP in critically ill patients may provide promising decision support for the application of PAC and may help to identify candidates who might benefit from PAC measurements or be harmed by PAC.
###end p 9
###begin title 10
Abbreviations
###end title 10
###begin p 11
BNP = brain natriuretic peptide; ICU = intensive care unit; IL = interleukin; LV = left ventricular; LVFP = left ventricular filling pressures; NT-proBNP = amino-terminal proBNP; PAC = pulmonary artery catheterization.
###end p 11
###begin title 12
Competing interests
###end title 12
###begin p 13
The authors declare that they have no competing interests.
###end p 13
###begin title 14
Acknowledgements
###end title 14
###begin p 15
This work was supported by a grant of the Faculty of Clinical Medicine Mannheim, University of Heidelberg, Germany.
###end p 15
###begin article-title 16
###xml 65 73 <span type="species:ncbi:9606">patients</span>
Natriuretic peptide testing for the evaluation of critically ill patients with shock in the intensive care unit: a prospective cohort study
###end article-title 16
###begin article-title 17
Breathing not properly multinational study intestigators: Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure
###end article-title 17
###begin article-title 18
B-type natriuretic peptide in cardiovascular disease
###end article-title 18
###begin article-title 19
###xml 87 95 <span type="species:ncbi:9606">patients</span>
A rapid test for B-type natriuretic peptide correlates with falling wedge pressures in patients treated for decompensated heart failure: a pilot study
###end article-title 19
###begin article-title 20
###xml 139 147 <span type="species:ncbi:9606">patients</span>
Canadian critical care clinical trials group: A randomized controlled trial of the use of pulmonary-artery catheters in high-risk surgical patients
###end article-title 20
###begin article-title 21
###xml 87 95 <span type="species:ncbi:9606">patients</span>
The effectiveness of right heart catheterization in the initial care of critically ill patients
###end article-title 21
###begin article-title 22
Toward an epidemiology and natural history of SIRS (systemic inflammatory response syndrome)
###end article-title 22
###begin article-title 23
###xml 71 79 <span type="species:ncbi:9606">patients</span>
Prognostic value of plasma N-terminal pro-brain natriuretic peptide in patients with severe sepsis
###end article-title 23
###begin article-title 24
Marked elevations in N-terminal brain natriuretic peptide levels in septic shock
###end article-title 24
###begin article-title 25
Plasma atrial natriuretic peptide and brain natriuretic peptide are increased in septic shock: impact of interleukin-6 and sepsis-associated left ventricular dysfunction
###end article-title 25
###begin article-title 26
###xml 2 4 2 4 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 128 136 <span type="species:ncbi:9606">patients</span>
NH2 terminal pro-brain natriuretic peptide plasma level as an early marker of prognosis and cardiac dysfunction in septic shock patients
###end article-title 26
###begin article-title 27
Brain natriuretic peptide: A marker of myocardial dysfunction and prognosis during severe sepsis
###end article-title 27
###begin article-title 28
Utility of B-type natriuretic peptide for the evaluation of intensive care unit shock
###end article-title 28
###begin article-title 29
Relationship between B-type natriuretic peptides and pulmonary capillary wedge pressure in the intensive care unit
###end article-title 29
###begin article-title 30
###xml 111 114 <span type="species:ncbi:10116">rat</span>
Transcriptional activation of the BNP gene by lipopolysaccharide is mediated through GATA elements in neonatal rat cardiac myocytes
###end article-title 30
###begin article-title 31
###xml 36 41 <span type="species:ncbi:9606">human</span>
Interleukin-1beta regulation of the human brain natriuretic peptide promoter involves Ras-, Rac-, and p38 kinase-dependent pathways in cardiac myocytes
###end article-title 31
###begin article-title 32
###xml 97 100 <span type="species:ncbi:10116">rat</span>
Involvement of cardiothrophin-1 in cardiac myocyte-nonmyocyte interactions during hypertrophy of rat cardiac myocytes in vitro
###end article-title 32
###begin article-title 33
###xml 53 56 <span type="species:ncbi:10116">rat</span>
Mechanical stretch activates the JAK/STAT pathway in rat cardiomyocytes
###end article-title 33

